Continuous Lumbar Plexus Block for Postoperative Pain Control After Total Hip Arthroplasty
NCT ID: NCT00790179
Last Updated: 2008-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
225 participants
INTERVENTIONAL
2003-01-31
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lumbar Plexus Block for Postoperative Pain Control After Hip Arthroscopy. A Randomized Controlled Trial
NCT01286805
Compare Epidural vs. Lumbar Plexus Analgesia After Hip Arthroplasty
NCT02493621
Evaluation of Efficacy of Lumbar Plexus Bloc After Hip Surgery
NCT00150865
Lumbar Plexus and Suprainguinal Fascia Iliaca Blocks For Total Hip Replacement
NCT03744065
Continuous L2 Paravertebral Block Versus Continuous Lumbar Plexus Block for Postoperative Analgesia
NCT01571492
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PCA;active comparator
Patients with intravenous PCA hydromorphone alone
continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA
0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.
Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.
CFB
Patients with a continuous femoral block (CFB) + PCA hydromorphone
continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA
0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.
Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.
CLPB
Patients with a continuous lumbar plexus block + PCA hydromorphone
continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA
0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.
Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA
0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.
Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* primary diagnosis of osteoarthritis
Exclusion Criteria
* peripheral neuropathy
* opioid dependency
* dementia
* coagulopathy
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northwell Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Huntington Hospital, North Shore-LIJ Health System
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph Marino, M.D.
Role: PRINCIPAL_INVESTIGATOR
Huntington Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1989md
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.